Company Overview and News

 
RPT-HK firms in China charm-push ahead of HK-Shenzhen investment link

2016-11-21 reuters
SHANGHAI, Nov 20 Scores of Hong Kong-listed companies - many small - are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

 
Hong Kong Firms Turn On the Charm Ahead of Shenzhen Investment Link

2016-11-20 fortune
Scores of Hong Kong-listed companies—many small—are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

 
Hong Kong firms in China charm-push ahead of Hong Kong-Shenzhen investment link

2016-11-20 channelnewsasia
SHANGHAI: Scores of Hong Kong-listed companies: many small: are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

 
Hong Kong firms in China charm-push ahead of Hong Kong-Shenzhen investment link

2016-11-20 reuters
SHANGHAI Scores of Hong Kong-listed companies - many small - are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

 
Global Facial Injectables Market 2016-2020

2016-10-12 prnewswire
NEW YORK, Oct. 12, 2016 /PRNewswire/ -- About Injectables Injectables are a combination of dermal fillers and Botox used in facial aesthetic treatments, which help reduce wrinkles and play a crucial role in rejuvenating facial skin for smoother and younger look. These are injected under the skin or lips to plump up the tissues and gently lift it to restore collagen lost due to aging. Collagen and HA provide essential support to skin and help it retain its elasticity.

 
Week In Review: Korea's Hanmi Signs $4.2 Billion Deal With Sanofi

2016-09-18 seekingalpha
Hanmi Pharma (KSE: 128940) of Korea out-licensed global rights for three long-acting diabetes drugs to Sanofi (NYSE: SNY) in a deal worth $4.2 billion (see story). Hanmi will receive $435 million upfront and up to $3.8 billion in milestones plus royalties on sales. Hanmi is on a roll. Earlier this year, the company out-licensed a novel lung cancer therapeutic to Boehringer Ingelheim for $730 million and sold the rights for an autoimmune drug to Lilly (NYSE: LLY) for $690 million.

 
Millennials' 'lunch-break cosmetics' spur China botox boom

2016-03-28 nzherald.co.nz
Fretting about frown lines and crow's feet can start early. In China, women in their 20s and 30s are spending on therapies to smooth their wrinkles -- a growing trend Union Medical Healthcare Ltd. wants to meet.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...